Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Traneurocin - NeuroActiva

Next Previous
Drug Profile

Traneurocin - NeuroActiva

Alternative Names: BIOCOVAX; BIOMEDIVIR; Cyclo(prolylglycyl); DEXANEUROSONE; NA 831; NANOMEDIVIR; NEUROSIVIR; TRANEUROCINE

Latest Information Update: 08 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroActiva
  • Developer Biomed Industries; Florey Institute of Neuroscience and Mental Health; NeuroActiva
  • Class Antidementias; Antivirals; Neuroprotectants; Nootropics; Peptides; Small molecules
  • Mechanism of Action AMPA receptor agonists; Neurogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Alzheimer's disease; COVID 2019 infections
  • Phase II Fragile X syndrome; Rett syndrome
  • Phase I Major depressive disorder
  • No development reported Neurological disorders

Most Recent Events

  • 27 Jul 2025 Phase-III clinical trials in Alzheimer's disease (Combination therapy, In adults, In the elderly) in USA (PO) prior to July 2025
  • 27 Jul 2025 Phase-III clinical trials in Alzheimer's disease (Monotherapy, In adults, In the elderly) in USA (PO) prior to July 2025
  • 27 Jul 2025 Updated efficacy and adverse event data from a phase IIa trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top